The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Inhibikase Therapeutics Inc shares valued at $2,999,999 were purchased by Sands Capital Life Sciences Pu on Nov 21 ’25. At $1.45 per share, Sands Capital Life Sciences Pu acquired 2,068,965 shares. The insider’s holdings grew to 13,018,965 shares worth approximately $19.66 million following the completion of this transaction.
As published in a research note from H.C. Wainwright on February 12, 2025, Inhibikase Therapeutics Inc [IKT] has been rated down from a Buy to a Neutral.
Analyzing IKT Stock Performance
On last trading session, Inhibikase Therapeutics Inc [NASDAQ: IKT] rose 4.86% to $1.51. The stock’s lowest price that day was $1.45, but it reached a high of $1.56 in the same session. During the last five days, there has been a drop of approximately -1.95%. Over the course of the year, Inhibikase Therapeutics Inc shares have dropped approximately -45.29%. Shares of the company reached a 52-week high of $3.4900 on 01/02/25 and a 52-week low of $1.3300 on 11/03/25.
Support And Resistance Levels for Inhibikase Therapeutics Inc (IKT)
According to the 24-hour chart, there is a support level at 1.4533, which, if violated, would cause prices to drop to 1.3967. In the upper region, resistance lies at 1.5633. The next price resistance is at 1.6167. RSI (Relative Strength Index) is 48.01 on the 14-day chart, showing neutral technical sentiment.
Is Inhibikase Therapeutics Inc subject to short interest?
Stocks of Inhibikase Therapeutics Inc saw a sharp steep in short interest on 2025-11-14 dropping by -0.11 million shares to 3.09 million. Data from Yahoo Finance shows that the short interest on 2025-10-15 was 3.2 million shares. A decline of -3.55% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 27.32 of the overall float, the days-to-cover ratio (short ratio) decline to 27.32.
Which companies own the most shares of Inhibikase Therapeutics Inc (IKT)?
In terms of Inhibikase Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 6.5 in the next 12 months, up nearly 351.39% from the previous closing price of $1.44. Analysts anticipate Inhibikase Therapeutics Inc stock to reach 8 by 2025, with the lowest price target being 5. In spite of this, 2 analysts ranked Inhibikase Therapeutics Inc stock as Buy at the end of 2025.
